Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie av ALV-100 for å vurdere sikkerhet, tolerabilitet og PK/PD hos overvektige/overvektige deltakere med eller uten T2D

15. oktober 2026 oppdatert av: Alveus Therapeutics, Inc.

En fase 1b, randomisert, dobbeltblind, placebokontrollert, dose-eskaleringsstudie som vurderer sikkerhet, tolerabilitet, farmakokinetikk og farmakodynamikk for ALV-100 hos deltakere med overvekt eller fedme med eller uten type 2-diabetes

A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

180

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Florida
      • Miami, Florida, Forente stater, 33172
        • Clinical Pharmacology of Miami
    • Ohio
      • Columbus, Ohio, Forente stater, 43212
        • Ohio Clinical Trials
    • Texas
      • San Antonio, Texas, Forente stater, 78240
        • Endeavor Clinical Trials

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

For Part A and B

  • Adult male and female participants, aged 18 to 65 years, inclusive, at the time of signing the informed consent form
  • Body mass index between 27.0 to 39.9 kg/m2 at Screening, both inclusive; overweight should be due to excess adipose tissue, as judged by the Investigator.
  • Have a stable body weight (< 5.0 kg/11 lbs self-reported change) within 90 days prior to Screening
  • Females must be surgically sterile (by means of bilateral salpingectomy, hysterectomy or bilateral oophorectomy) or be post-menopausal (defined as spontaneous cessation of menses for at least 1 year prior to Screening). Females who are post-menopausal and < 55 years must have a follicle-stimulating hormone level > 40 IU/L at Screening.
  • Males with female partners of child-bearing potential must be willing to practice abstinence or must agree to use condom as contraception throughout the duration of the study. This criterion may be waived for male participants who have had a documented successful vasectomy > 6 months before signing the ICF.

For Part B only

  • Diagnosis of Type 2 Diabetes for at least 180 days prior to Screening.
  • Glycemic control managed by diet and exercise alone or by stable treatment with metformin and/or sodium-glucose cotransporter 2 inhibitors (SGLT-2i), with no dose changes within 3 months prior to Screening.
  • Hemoglobin A1c (HbA1c) between 6.5 % and 9.0% (equivalent to 48-75 mmol/mol), both inclusive, at Screening.

Exclusion Criteria:

For Part A and B

  • History or presence of any clinically relevant respiratory, metabolic (including dyslipidemia, however screening total cholesterol below or equal to 302 mg/dL (7.8 mmol/L) and/or screening triglyceride below or equal to 500 mg/dL (5.65 mmol/L) is accepted), renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with type 2 diabetes in Part B) at the discretion of the Investigator.
  • Participants with a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 or a personal history of nonfamilial medullary thyroid carcinoma.
  • Current or history of chronic or acute pancreatitis.
  • Obesity caused by known endocrinologic disorders (e.g., Cushing syndrome) or monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndrome).
  • History of major depressive disorder or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or anxiety disorder).
  • Lifetime history of a suicide attempt or of any suicidal behavior by endorsement of (answered yes to) any of the items in the suicidal behavior section on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening.
  • Systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at Screening.
  • History of or current cardiovascular disease, including but not limited to stable and unstable angina, myocardial infarction, congestive heart failure, transient ischemic attack, stroke, clinically significant arrhythmias and conduction disorders or venous thromboembolism.

Part A only

• History or clinical evidence of Type 1 or Type 2 diabetes mellitus, including HbA1c ≥ 6.5% and/or a fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) at Screening (female participants with a history of gestational diabetes are allowed).

Part B only

  • Fasting plasma glucose (FPG) > 270 mg/dL (15.0 mmol/L) at Screening.
  • Proliferative retinopathy or maculopathy as judged by the investigator based on a recent (within1.5 years from Screening) ophthalmologic examination.
  • Severe neuropathy as judged by the investigator.
  • Advanced nephropathy (defined as albuminuria ≥ 300 mg/g).
  • History of severe hypoglycemia or hypoglycemic unawareness as judged by the investigator.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part A - Cohort 1 (ALV-100)

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Participants will receive multiple ascending doses of ALV-100.

Placebo komparator: Part A - Cohort 1 (Placebo)

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

Participants will receive placebo matching ALV-100, volume-matched to active dose.

Eksperimentell: Part A - Cohort 2 (ALV-100)

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Participants will receive multiple ascending doses of ALV-100.

Placebo komparator: Part A - Cohort 2 (Placebo)

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

Participants will receive placebo matching ALV-100, volume-matched to active dose.

Eksperimentell: Part A - Cohort 3 (ALV-100)

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Participants will receive multiple ascending doses of ALV-100.

Placebo komparator: Part A - Cohort 3 (Placebo)

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

Participants will receive placebo matching ALV-100, volume-matched to active dose.

Eksperimentell: Part A - Cohort 4 (ALV-100)

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Participants will receive multiple ascending doses of ALV-100.

Placebo komparator: Part A - Cohort 4 (Placebo)

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

Participants will receive placebo matching ALV-100, volume-matched to active dose.

Eksperimentell: Part B - T2D Cohort (ALV-100)

Participants with overweight or obesity with type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Participants will receive multiple ascending doses of ALV-100.

Placebo komparator: Part B - T2D Cohort (Placebo)

Participants with overweight or obesity with type 2 diabetes will receive placebo by subcutaneous injection.

Participants will receive placebo matching ALV-100, volume-matched to active dose.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety and tolerability
Tidsramme: From First Dose to Week 52

Incidence of treatment emergent adverse events (TEAEs)

From First Dose to Week 52

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pharmacokinetics (PK) of intact ALV-100 and total ALV-100 - Cmax, MD
Tidsramme: From First Dose to Week 52

Maximum observed serum concentration after multiple doses (MD) (Cmax, MD)

From First Dose to Week 52
Pharmacokinetics (PK) of intact ALV-100 and total ALV-100 - AUC(0-τ), MD
Tidsramme: From First Dose to Week 52

Area under the serum concentration-time curve from time zero to τ, where τ is the dosing interval, (AUC(0-τ), MD)

From First Dose to Week 52
Pharmacodynamic (PD) impact on body weight
Tidsramme: Baseline, Week 32 and Week 52

Change from baseline in body weight

Baseline, Week 32 and Week 52
Pharmacodynamic (PD) impact on body weight percentage
Tidsramme: Baseline, Week 32 and Week 52

Change from baseline in body weight percentage

Baseline, Week 32 and Week 52
Immunogenicity
Tidsramme: From Baseline to Week 52

Incidence of Anti-ALV-100 drug antibodies, including assessments of cross-reactivity and neutralizing antibodies.

From Baseline to Week 52
Relationship between ALV-100 serum concentration and QTc interval changes (Part A Only)
Tidsramme: From First Dose to Week 52

Measurement of change in individual specific heart rate corrected QT interval (QTcI) and Fridericia heart rate corrected QT interval (QTcF) on 12-lead ECG.

From First Dose to Week 52
Paracetamol (acetaminophen) absorption test (PAT) (Part A Only)
Tidsramme: From First Dose to Week 52

Measurement of acetaminophen PK parameters to evaluate the effect of ALV-100 on the gastric emptying rate.

From First Dose to Week 52
Pharmacodynamic (PD) impact of ALV-100 on antidiabetic medication (Part B Only)
Tidsramme: From Baseline to Week 32

Change in use of concomitant glucose-lowering medication

From Baseline to Week 32
Pharmacodynamic (PD) impact of ALV-100 on glycemic parameters (Part B Only)
Tidsramme: Week 32 and Week 52

Measuring the number of participants achieving target Hemoglobin A1c values

Week 32 and Week 52
Hypoglycemic Safety (Part B Only)
Tidsramme: From Baseline to Week 52

Measured by the incidence of symptomatic hypoglycemia, documented symptomatic hypoglycemia and severe hypoglycemia

From Baseline to Week 52

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Karen Tornøe, MD, PhD, Alveus Therapeutics

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

29. desember 2025

Primær fullføring (Antatt)

1. oktober 2027

Studiet fullført (Antatt)

1. oktober 2027

Datoer for studieregistrering

Først innsendt

15. januar 2026

Først innsendt som oppfylte QC-kriteriene

3. februar 2026

Først lagt ut (Faktiske)

10. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere